MACK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MACK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Merrimack Pharmaceuticals's book value per share for the quarter that ended in Dec. 2023 was $1.31.
During the past 12 months, Merrimack Pharmaceuticals's average Book Value Per Share Growth Rate was -3.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 3.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Merrimack Pharmaceuticals was 84.10% per year. The lowest was -185.80% per year. And the median was 1.50% per year.
Merrimack Pharmaceuticals's current price is $14.73. Its book value per share for the quarter that ended in Dec. 2023 was $1.31. Hence, today's PB Ratio of Merrimack Pharmaceuticals is 11.28.
During the past 13 years, the highest P/B Ratio of Merrimack Pharmaceuticals was 43.72. The lowest was 9.88. And the median was 43.72.
The historical data trend for Merrimack Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merrimack Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Book Value per Share | Get a 7-Day Free Trial | 1.29 | 1.20 | 1.06 | 1.35 | 1.31 |
Merrimack Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Book Value per Share | Get a 7-Day Free Trial | 1.35 | 1.35 | 1.33 | 1.31 | 1.31 |
For the Biotechnology subindustry, Merrimack Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Merrimack Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Merrimack Pharmaceuticals's PB Ratio falls into.
Merrimack Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (18.75 | - | 0.00) | / | 14.35 | |
= | 1.31 |
Merrimack Pharmaceuticals's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (18.75 | - | 0.00) | / | 14.35 | |
= | 1.31 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Merrimack Pharmaceuticals (NAS:MACK) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric Andersen | director, other: See Remarks | 1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404 |
Gary L Crocker | director, officer: President | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Noah G. Levy | director, other: See Remarks | 60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165 |
Ana Radeljevic | director | 2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467 |
Ulrik B. Nielsen | director | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Russell T Ray | director | 2525 DUPONT DR, IRVINE CA 92612 |
Newtyn Capital Partners, Lp | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Ledo Capital, Llc | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Newtyn Te Partners, Lp | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Newtyn Partners, Lp | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Western Standard Partners Qp, L.p. | other: See Remarks | 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036 |
Western Standard Partners Lp | other: See Remarks | 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036 |
Western Standard Llc | other: See Remarks | 5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036 |
Newtyn Management, Llc | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
22nw Gp, Inc. | 10 percent owner, other: See Explanation of Responses | 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107 |
From GuruFocus
By PRNewswire PRNewswire • 07-25-2019
By Business Wire Business Wire • 05-08-2020
By Marketwired Marketwired • 04-12-2019
By Business Wire • 08-03-2023
By Business Wire Business Wire • 11-05-2020
By Business Wire Business Wire • 11-03-2022
By PRNewswire PRNewswire • 11-07-2018
By Business Wire Business Wire • 08-03-2022
By Business Wire Business Wire • 08-05-2021
By Business Wire Business Wire • 08-04-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.